Samsung Electronics отказывается от услуг китайского производителя аккумуляторов Amperex Technology (ATL), чья продукция стала причиной массового отзыва флагманских смартфонов Galaxy Note 7. Об этом сообщает технопортал ET News, получивший информацию из осведомлённых источников. По их сведениям, новый Galaxy Note 8, который представят уже 23 августа, будет использовать батарею ёмкостью 3300 мА·ч производства Samsung SDI и японской Murata Manufacturing. Эти компании поделили заказы в соотношении 80 % на 20 %. Samsung и ATL сотрудничали более 10-ти лет, однако партнёрские связи оказались под угрозой разрыва после того, как южнокорейский вендор был вынужден полностью отозвать более 3 миллионов Galaxy Note 7 из-за взрывоопасных аккумуляторов. Как сообщалось ранее, проблема с батареями ATL заключалась в производственном браке, а также отсутствии изоляции (или несовпадении с изолируемым контактом) и в излишне тонких разделительных перегородках. И хотя дефектные аккумуляторы для Galaxy Note 7 также поставлялись от Samsung SDI, последний принял все необходимые меры, чтобы история не повторилась. После инцидента в Samsung значительно усилен контроль над собственным подразделением SDI, но с ATL возникли проблемы. Компании не пришли к соглашению по таким ключевым вопросам, как применение неиспользованных аккумуляторов и выплата компенсаций, указывают отраслевые источники. К тому же ATL не готова вкладывать огромные средства в усиление контроля качества выпускаемой продукции, как это делает Samsung. Тем не менее сотрудничество между Samsung и ATL может сохраниться в области поставок аккумуляторов для бюджетных моделей смартфонов, где не требуется использование высокопрецизионных технологий. Samsung Electronics Uses Batteries from Samsung SDI and Murata for Galaxy Note 8 Batteries from Samsung SDI and Japan’s Murata are used for Samsung Electronics’ Galaxy Note 8. Products from China’s ATL, which is Samsung Electronics’ long-time partner, have not been used again for Samsung Electronics’ Smartphones. It seems that partnership between Samsung Electronics and ATL is becoming distant after recall of Galaxy Note 7 that happened last year and that Murata is replacing ATL’s position. According to industries on the 20th, it is confirmed that Samsung Electronics has decided to use batteries from Samsung SDI and Murata Manufacturing for its new Smartphone called ‘Galaxy Note 8’ followed by ‘Galaxy S8’ that was released during first half of this year. Samsung SDI and Murata are going to be responsible for supplying 80% and 20% of 3,300mAh batteries that will be used for Galaxy Note 8. However entire initial supply of batteries will be supplied by Samsung SDI. Murata Manufacturing is a business that acquired SONY’s battery business in 2016 and is the number one business in global MLCC (Multilayer Ceramic Condenser) markets. China’s ATL is devastated again as Samsung Electronics has decided to use batteries from Samsung SDI and Murata Manufacturing. Samsung Electronics has not used batteries from ATL for ‘Galaxy S8’ and ‘Galaxy Note 8’. ATL has been a partner of Samsung Electronics for more than 10 years. ATL’s batteries were also used for Galaxy Note 7 that was released last year. Industries are predicting that Samsung’s replacement of its battery supplier is happening due to ignition of Galaxy Note 7 that led to discontinuation of Galaxy Note 7. Samsung Electronics pointed out defect of batteries as the cause for ignition of Galaxy Note 7 in this past January. At that time, Samsung announced that ATL’s batteries caused ignition due to irregular asperity welding, unattached insulation tape, and thin separator. It is heard that Samsung Electronics had maintained partnership with ATL even after ATL’s batteries caused ignition of Galaxy Note 7s and was looking into adding Murata Manufacturing as a battery supplier. However it is heard that ATL was ultimately removed as a battery supplier of Samsung Electronics as Samsung Electronics and ATL had different views when it came to establishing solutions to prevent recurrence of ignition of batteries. “It seems that Samsung Electronics and ATL had different views on investigation on causes of ignition of Galaxy Note 7, handling of current supplies that are ordered, and compensation.” said a representative for an industry. “Although there is a chance that they will work again for some low-grade models or models for foreign countries, Samsung Electronics has decided not to use ATL’s batteries for its premium Smartphones.” “It seems that when Samsung Electronics enforced standards for tests after discontinuation and recall of Galaxy Note 7, ATL was not thrilled about purchasing additional test equipment and meddling from Samsung Electronics.” said a representative for a different industry. “For ATL, it is not something that they will be totally devastated about since amount of batteries that it sent to Samsung Electronics was not relatively huge and it still has Apple as its biggest customer.” Samsung Electronics greatly upgraded its quality management system such as 8-point battery safety inspection after it had gone through hard time due to ignition of Galaxy Note 7. Although it is relatively easy for Samsung SDI, which is Samsung Electronics’ biggest battery supplier for Galaxy series, to make investments and to cooperate according to Samsung Electronics’ guidelines, it is different from ATL’s point of view. ATL is currently the number one business in the world when it comes to polymer batteries as it has been supplying batteries to Apple for more than 10 years. It seems that Samsung Electronics will use batteries from Murata Manufacturing instead of ATL for its premium Smartphones that will be released after Galaxy Note 8. It is heard that Murata is also participating in supply of batteries for Galaxy S9 that will be released during first half of next year. As Samsung Electronics decides to use batteries from Murata, it now has to raise production capacity and quality of Murata Manufacturing to the level of ATL. Although SONY’s battery business, which was acquired by Murata, became the first business in the world to commercialize lithium-ion batteries in 1991, its status in small battery markets has gotten lower recently.
Сегодня представители Samsung Electronics сообщили, что корпорация планирует к 2020 году задействовать использование интеллектуальных функций в своих бытовых приборах, включая интернет-вещание и распознавание голосовых команд с помощью виртуального помощника Bixby. Для того, чтобы "эпоха умных домов" наступила как можно быстрее, южнокорейский техногигант прилагает большие усилия. Образцы грядущей технологической революции от Samsung будут представлены уже через неделю на крупнейшей выставке потребительской электроники IFA 2017 в столице Германии. В Samsung заявили, что корпорация нацелена на создание единой платформы, где вся бытовая техника соединена друг с другом через программы искусственного интеллекта. Менеджеры Samsung добавили, что вендор планирует использовать приложение Samsung Connect для управления всеми бытовыми приборами с помощью технологии облачных вычислений. Как сообщает бизнес-портал The Investor, в корпорации отметили, что порядка 130 IoT-девайсов могут быть связаны через Samsung Connect, причём со временем их номенклатура будет расширяться. Samsung to apply smart features to home appliances Samsung Electronics said on Aug. 22 that it plans to apply smart features, such as Internet-of-Things and voice recognition, to its home appliances lineup by 2020. The Korean tech giant said it has been making efforts to prepare for what it calls “the era of smart homes,” announcing it will introduce details of its vision during the IFA 2017 slated for next month. Samsung said its vision aims to establish a platform where home appliances connect each other through artificial-intelligence programs. The company added it plans to have a “Samsung Connect” application to control all home appliances through the cloud computing technology. The company said 130 products can be linked to Samsung Connect, and the scope of the service will expand down the road.
Биофармацевтическое подразделение Samsung Bioepis Co Ltd и крупнейшая в Азии японская фармацевтическая компания Takeda Pharmaceutical Co Ltd подписали соглашение о стратегическом партнёрстве по софинансированию и совместным разработкам нескольких новых препаратов и методов лечения. "Первой ласточкой" в реализации совместной программы станет препарат для лечения тяжелого острого панкреатита TAK-671. Партнёрство по распределению рисков объединяет платформу для развития биотехологии Samsung Bioepis с лучшими в своём классе экспертами в области разработки лекарств, чтобы совместно финансировать и разрабатывать инновационные методы лечения, сообщили представителий обеих компаний. Дополнительные условия сотрудничества не разглашаются, сообщает пресс-служба Samsung Bioepis. Биофармацевтическая компания Samsung Bioepis основана в 2012 году. Благодаря инновациям в разработке продуктов и твёрдой приверженности качеству продвигает широкий спектр биосимиляров, в том числе в иммунологии, онкологии и для страдающих диабетом. Компания является совместным предприятием Samsung BioLogics и Biogen. За 5 лет своего существования Samsung Bioepis инвестировал $1,3 миллиарда в развитие биопрепаратов и получил одобрение двух своих биосимиляров в Европе и одного в США, сообщает портал BusinessKorea. Samsung Bioepis Teams up with Japan’s Takeda to Develop Novel Biotech Drugs Samsung Bioepis and Japan's Takeda Pharmaceutical will co-fund and collaboratively develop innovative therapies rather than transferring new candidate materials or technologies. Samsung Bioepis Co., a biopharmaceutical affiliate of Samsung, announced on August 21 it has entered into a strategic collaboration agreement with Japan's Takeda Pharmaceutical Co., the largest pharmaceutical company in Asia, to jointly develop novel biologic drugs. The latest agreement is to create a synergy between Samsung Bioepis’ biologics development platform and technologies and Takeda’s extensive knowledge and expertise in drug development. Under the agreement, the two companies will collaboratively work on the whole process of new material searching, clinical trial, licensing and commercialization. In particular, the two companies will co-fund and collaboratively develop innovative therapies rather than transferring new candidate materials or technologies. Samsung Bioepis said, “We have decided to participate in the development of biologic medicines beyond biosimilars in order to provide effective biologic drugs.” The deal marks a milestone for the biopharma development unit of Samsung Group, launched as part of the conglomerate’s future businesses initiated seven years ago by its currently bedridden Chairman Lee Kun-hee in May 2010. It was also the achievement in five years after Samsung Bioepis was founded in 2012 with an aim of biologics research and development and commercialization. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis, and expand to other novel biologic treatments in the future. TAK-671 is a candidate material developed by Takeda Pharmaceutical. Samsung Bioepis said the two companies thought that it is the right time to jointly carry out clinical trials with the new candidate material since the clinical trials haven’t started yet. In addition, there is a high demand for acute pancreatitis because there are no treatments for the disease yet and Takeda Pharmaceutical has expertise in gastrointestinal internal medicines. Accordingly, Samsung Bioepis will take part in the preclinical studies on TAK-671 and jointly carry out the Phase I clinical trial with Takeda Pharmaceutical next year. In general, pharmaceutical companies search and develop a candidate material and conduct preclinical studies, including animal testing, and carry out Phase I to III clinical trials in order to develop novel drugs. Takeda Pharmaceutical, which is Asia’s biggest multinational pharmaceutical company founded in 1781, posted US$16.1 billion (18.38 trillion won) in sales last year. Until now, some have pointed out that Samsung Bioepis tends to focus on current profits rather than the future by developing biosimilars.
